Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit

Movement Disorders

Volumn 28, Issue 12, 2013, Pages 1675-1682

  Eskow Jaunarajs, Karen L ^a   Standaert, David G ^a   Viegas, Tacey X ^b   Bentley, Michael D ^b   Fang, Zhihao ^b   Dizman, Bekir ^b   Yoon, Kunsang ^b   Weimer, Rebecca ^b   Ravenscroft, Paula ^c   Johnston, Tom H ^c   Hill, Michael P ^c   Brotchie, Jonathan M ^c   Moreadith, Randall W ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Serina Therapeutics Inc   (United States)

^c Atuka Ltd   (Canada)

Author keywords

6 hydroxydopamine; Dopamine; Parkinson's disease; Rat; Rotigotine

Indexed keywords

ANTIPARKINSON AGENT; POLYOXAZOLINE; ROTIGOTINE; SER 214; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CIRCLING BEHAVIOR; CONJUGATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; FEMALE; FORELIMB; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION;

6-HYDROXYDOPAMINE; DOPAMINE; PARKINSON'S DISEASE; RAT; ROTIGOTINE;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; FEMALE; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84886390978     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25625     Document Type: Article

References (32)

1. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20:S11-S16.
2. Stocchi F. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol 2011;258:S316-S322.
3. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-897.
4. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47-S55.
5. Calon F, Hadj Tahar A, Blanchet PJ, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 2000;23:S92-S100.
6. Cenci MA. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 2002;23:105-109.
7. Kieburtz K. Therapeutic strategies to prevent motor complications in Parkinson's disease. J Neurol 2008;255:S42-S45.
8. Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 2012;18:S120-S122.
9. Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-DOPA in plasma by decreasing its peripheral metabolism independent of L-DOPA/carbidopa dose. Br J Clin Pharmacol 2002;54:363-371.
10. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
11. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
12. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29:S387-S388.
13. Devos D;French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
14. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-1085.
15. Antonini A, Odin P. Pros and cons of apomorphine and L-DOPA continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15:S97-S100.
16. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 2010;22:147-161.
17. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH;SP513 investigators. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-2404.
18. LeWitt PA, Lyons KE, Pahwa R;SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-1267.
19. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trail of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276.
20. Viadya A, Agarwal A, Jain A, Agrawal RK, Jain SK. Bioconjugation of polymers: a novel platform for targeted drug delivery. Curr Pharm Des 2011;17:1108-1125.
21. Adams N, Schubert US. Poly(2-oxazolines) in biological and biomedical application contexts. Adv Drug Deliv Rev 2007;59:1504-1520.
22. Hoogenboom R. Poly(2-oxazoline)s: a polymer class with numerous potential applications. Angew Chem Int Ed Engl 2009;48:7978-7994.
23. Mero A, Pasut G, Dall Via L, et al. Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J Control Release 2008;125:87-95.
24. Viegas TX, Bentley MD, Harris JM, et al. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem 2011;22:976-986.
25. Almeida AM, Castel-Branco MM, Falcao AC. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J Chromat 2002;774:215-222.
26. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000;20:7782-7789.
27. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism, and spinal cord injury. Neuropharmacology 2000;39:777-787.
28. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-S41.
29. Bershow A, Warshaw E. Cutaneous reactions to transdermal therapeutic strategies. Dermatitis 2011;22:193-203.
30. Fasano A, Guidubaldi A, De Nigris F, Bentivoglio AR. Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. J Amer Geriatr Soc 2011;59:2386-2387.
31. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
32. Jenner P, McCreary AC, Scheller DK. 2011. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011;118:1691-1702.